Overseed, a young company from Orléans (Loiret), recently received approval from the National Agency for the Safety of Medicines (ANSM) authorizing it to open the first "genetic and agronomic R & D" of therapeutic cannabis in France. .

The objective is to conduct various research in order to facilitate an upcoming pharmaceutical production of cannabis-based drugs, explains

La République du Center

.

Authorization from 2023?

2.5 million euros were also raised by the company created in January 2021 and hosted by the start-up incubator Agreen Lab'O in Orléans.

Five people are currently working there but hiring is expected soon.

For its part, the ANSM continues to conduct tests on more than 3,000 patients to determine whether cannabis drugs can be authorized in France by 2023.

Hugues Péribère, boss of Overseed, spoke of important outlets in France, with “hundreds of thousands of patients” interested.

Therapeutic cannabis would help fight pain, severe epilepsies, the side effects of chemotherapy or even Parkinson's disease.

Health

Why medical cannabis is primarily prescribed to relieve chronic pain

Health

Medical cannabis: The French experiment already brings together 1,000 patients out of 3,000 expected

  • Health

  • Processing

  • Cannabis

  • Orleans

  • Loiret

  • 0 comment

  • 0 share

    • Share on Messenger

    • Share on Facebook

    • Share on twitter

    • Share on Flipboard

    • Share on Pinterest

    • Share on Linkedin

    • Send by Mail

  • To safeguard

  • A fault ?

  • To print